IRC 003 - Combination Therapy Study
***IRC 003 has closed to enrollment at all participating research sites.***
What is IRC 003? IRC 003 is a medical research study that is evaluating whether treating influenza with three antiviral drugs (amantadine, ribavirin, and oseltamivir) will help symptoms resolve faster and with fewer complications than with oseltamivir (Tamiflu®) alone.
Who is eligible to volunteer for the study? Adults, at least 18 years old, who test positive for influenza and have a condition that increases their likelihood of developing complications of influenza. Some of these conditions include:
- Advanced age (65 years or older)
- Lung Disease such as COPD
- Heart Disease
- Blood and Kidney Disorders
- Body Mass Index (BMI) Greater than 40
If eligible, will I receive treatment? All eligible volunteers who are in the study will receive influenza treatment, either the combination therapy or oseltamivir alone. Also, study-related medications and medical exams will be provided at no charge, and volunteers may be compensated for their time.
How do I volunteer for the study? Please contact a participating research site in your area for more information if you:
- Start to experience any symptoms of influenza such as fever, cough, sore throat, stuffy or runny nose, sweats/chills, head or muscle aches
- Are an adult
- Have an existing medical condition that puts you at increased risk for complications from influenza
Please review the list of participating sites below and click on the site name for the address and phone number.
Additional information about this trial can be found on the ClinicalTrials.gov website, under the title: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications